147 related articles for article (PubMed ID: 6791053)
21. Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient.
Kulick SK; Kramer DA
Ann Emerg Med; 1993 Mar; 22(3):610-2. PubMed ID: 8192712
[TBL] [Abstract][Full Text] [Related]
22. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction.
Zaret BS; Beckner RR; Marini AM; Wagle W; Passarelli C
Neurology; 1982 Feb; 32(2):206-8. PubMed ID: 6798491
[TBL] [Abstract][Full Text] [Related]
23. Nutritional influence on serum ammonia in young patients receiving sodium valproate.
Laub MC
Epilepsia; 1986; 27(1):55-9. PubMed ID: 3081337
[TBL] [Abstract][Full Text] [Related]
24. Hepatic and renal contributions to valproic acid-induced hyperammonemia.
Marini AM; Zaret BS; Beckner RR
Neurology; 1988 Mar; 38(3):365-71. PubMed ID: 3126407
[TBL] [Abstract][Full Text] [Related]
25. Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.
Gerstner T; Buesing D; Longin E; Bendl C; Wenzel D; Scheid B; Goetze G; Macke A; Lippert G; Klostermann W; Mayer G; Augspach-Hofmann R; Fitzek S; Haensch CA; Reuland M; Koenig SA
Seizure; 2006 Sep; 15(6):443-8. PubMed ID: 16787750
[TBL] [Abstract][Full Text] [Related]
26. Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy.
Velioğlu SK; Gazioğlu S
Acta Neurol Scand; 2007 Aug; 116(2):128-32. PubMed ID: 17661800
[TBL] [Abstract][Full Text] [Related]
27. Hyperaminoacidemia in epileptic children treated with valproic acid.
Castro-Gago M; Rodrigo-Saez E; Novo-Rodriguez I; Camiña MF; Rodriguez-Segade S
Childs Nerv Syst; 1990 Dec; 6(8):434-6. PubMed ID: 2095300
[TBL] [Abstract][Full Text] [Related]
28. Free and total serum valproate concentrations: their relationship to seizure control, liver enzymes and plasma ammonia in children.
Farrell K; Abbott FS; Orr JM; Applegarth DA; Jan JE; Wong PK
Can J Neurol Sci; 1986 Aug; 13(3):252-5. PubMed ID: 3091231
[TBL] [Abstract][Full Text] [Related]
29. Risk factors for hyperammonemia in pediatric patients with epilepsy.
Yamamoto Y; Takahashi Y; Imai K; Mishima N; Yazawa R; Inoue K; Itoh K; Kagawa Y; Inoue Y
Epilepsia; 2013 Jun; 54(6):983-9. PubMed ID: 23409971
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for valproic acid induced hyperammonemia and its association with cognitive functions.
Duman B; Can KC; Ağtaş-Ertan E; Erdoğan S; İlhan RS; Doğan Ö; Kumbasar H; Çamsarı UM
Gen Hosp Psychiatry; 2019; 59():67-72. PubMed ID: 31276904
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.
Yamamoto Y; Takahashi Y; Suzuki E; Mishima N; Inoue K; Itoh K; Kagawa Y; Inoue Y
Epilepsy Res; 2012 Sep; 101(3):202-9. PubMed ID: 22542569
[TBL] [Abstract][Full Text] [Related]
32. Asymptomatic hyperammonemia in children treated with valproic acid.
Altunbaşak S; Baytok V; Tasouji M; Hergüner O; Burgut R; Kayrin L
J Child Neurol; 1997 Oct; 12(7):461-3. PubMed ID: 9373804
[No Abstract] [Full Text] [Related]
33. Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy.
Honeycutt D; Callahan K; Rutledge L; Evans B
Neurology; 1992 Mar; 42(3 Pt 1):666-8. PubMed ID: 1549234
[TBL] [Abstract][Full Text] [Related]
34. Carnitine deficiency and hyperammonemia associated with valproic acid therapy.
Ohtani Y; Endo F; Matsuda I
J Pediatr; 1982 Nov; 101(5):782-5. PubMed ID: 6813444
[TBL] [Abstract][Full Text] [Related]
35. [Role of hyperammonemia in stuporous states induced by sodium valproate].
Warter JM; Marescaux C; Rumbach L; Micheletti G; Chabrier G; Koehl C; Imler M; Collard M
Rev Neurol (Paris); 1983; 139(12):753-7. PubMed ID: 6420866
[TBL] [Abstract][Full Text] [Related]
36. Reversible valproic acid-induced dementia: a case report.
Zaret BS; Cohen RA
Epilepsia; 1986; 27(3):234-40. PubMed ID: 3084231
[TBL] [Abstract][Full Text] [Related]
37. [Sodium valproate: a hyperammonemic drug. Study in the epileptic and healthy volunteer].
Marescaux C; Warter JM; Laroye M; Rumbach L; Micheletti G; Koehl C; Imler M; Kurtz D
J Neurol Sci; 1983 Feb; 58(2):195-209. PubMed ID: 6403673
[TBL] [Abstract][Full Text] [Related]
38. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
Zhu X; Li X; Zhang T; Zhao L
Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
[TBL] [Abstract][Full Text] [Related]
39. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
Goto S; Seo T; Hagiwara T; Ueda K; Yamauchi T; Nagata S; Ando Y; Ishitsu T; Nakagawa K
J Pharm Pharmacol; 2008 Feb; 60(2):267-72. PubMed ID: 18237476
[TBL] [Abstract][Full Text] [Related]
40. Valproate-associated hyperammonemia and DL-carnitine supplement.
Komatsu M; Kodama S; Yokoyama S; Konishi H; Tanaka K; Momota K; Wada H; Matsuo T
Kobe J Med Sci; 1987 Jun; 33(3):81-7. PubMed ID: 2959815
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
